{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:55:08Z","timestamp":1781646908649,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    MODY (Maturity-Onset Diabetes of the Young) is characterized by autosomal dominant mode of inheritance, early onset of diabetes in the absence of autoimmunity directed to pancreatic \u03b2-cells, impaired insulin secretory capacity, however, maintained over time, and extra-pancreatic manifestations in some patients. Its prevalence has been estimated 0.6% to 6.5% of all diabetes in Europe and the USA. Pathogenic variants in the genes encoding glucokinase or transcription factors\n                    <jats:italic>HNF1A<\/jats:italic>\n                    or\n                    <jats:italic>HNF4A<\/jats:italic>\n                    are responsible for the majority of cases of monogenic forms of diabetes referred to as MODY. The objective of the French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins) dedicated to\n                    <jats:italic>GCK<\/jats:italic>\n                    -MODY (formerly MODY2),\n                    <jats:italic>HNF1A<\/jats:italic>\n                    -MODY (MODY3), and\n                    <jats:italic>HNF4A<\/jats:italic>\n                    -MODY (MODY1) is to provide to health professionals a guide for optimal management and care of patients, based on a critical literature review and multidisciplinary expert consensus. The PNDS, written by members of the French National Reference Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), is available on the French Health Authority website (in French). Thorough analysis of personal and family history, clinical examination and biochemical testing are key to raise the diagnosis, which has to be confirmed by molecular analysis. The attending physician, in conjunction with the national care network, will ensure that the patient receives optimal care through regular follow-up and screening. Overall, the management of patients with MODY requires the collaboration of several health care providers.\n                  <\/jats:p>","DOI":"10.1186\/s13023-026-04272-y","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:58:40Z","timestamp":1774958320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins)"],"prefix":"10.1186","volume":"17","author":[{"given":"Dani\u00e8le","family":"Dubois-Laforgue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-4782","authenticated-orcid":false,"given":"Bruno","family":"Donadille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Ciangura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Amouyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Barat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Beltrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Bismuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Carel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Cav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Christin-Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Collin-Chavagnac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Damg\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Delemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gourdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jacqueminet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Janmaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Kerdanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Langin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Nault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Nizard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Saint-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tauveron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Val\u00e9ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vambergue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Vatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Nicolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bellann\u00e9-Chantelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"4272_CR1","doi-asserted-by":"publisher","unstructured":"Zhang H, Colclough K, Gloyn AL, Pollin TI. Monogenic diabetes: a gateway to precision medicine in diabetes. J Clin Invest. 2021;131:e142244. https:\/\/doi.org\/10.1172\/JCI142244.","DOI":"10.1172\/JCI142244"},{"key":"4272_CR2","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.2337\/dci20-0065","volume":"43","author":"MC Riddle","year":"2020","unstructured":"Riddle MC, Philipson LH, Rich SS, Carlsson A, Franks PW, Greeley SAW, et al. Monogenic diabetes: from genetic Insights to population-based precision in Care. Reflections a Diabetes care editors\u2019 expert forum. Diabetes Care. 2020;43:3117\u201328. https:\/\/doi.org\/10.2337\/dci20-0065.","journal-title":"Reflections a Diabetes Care Editors\u2019 Expert Forum. Diabetes Care"},{"key":"4272_CR3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s00125-022-05720-7","volume":"65","author":"A Bonnefond","year":"2022","unstructured":"Bonnefond A, Semple RK. Achievements, prospects and challenges in precision care for monogenic insulin-deficient and insulin-resistant diabetes. Diabetologia. 2022;65:1782\u201395. https:\/\/doi.org\/10.1007\/s00125-022-05720-7.","journal-title":"Diabetologia"},{"key":"4272_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s43856-023-00369-8","volume":"3","author":"R Murphy","year":"2023","unstructured":"Murphy R, Colclough K, Pollin TI, Ikle JM, Svalastoga P, Maloney KA, et al. The use of precision diagnostics for monogenic diabetes: a systematic review and expert opinion. Commun Med. 2023;3:136. https:\/\/doi.org\/10.1038\/s43856-023-00369-8.","journal-title":"Commun Med"},{"key":"4272_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2337\/dc17-0224","volume":"40","author":"BM Shields","year":"2017","unstructured":"Shields BM, Shepherd M, Hudson M, McDonald TJ, Colclough K, Peters J, et al. Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care. 2017;40:1017\u201325. https:\/\/doi.org\/10.2337\/dc17-0224.","journal-title":"Diabetes Care"},{"key":"4272_CR6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2337\/dc21-2056","volume":"45","author":"L Pang","year":"2022","unstructured":"Pang L, Colclough KC, Shepherd MH, McLean J, Pearson ER, Ellard S, et al. Improvements in awareness and testing have led to a threefold increase over 10 years in the identification of monogenic diabetes in the U.K. Diabetes Care. 2022;45:642\u201349. https:\/\/doi.org\/10.2337\/dc21-2056.","journal-title":"Diabetes Care"},{"key":"4272_CR7","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1210\/jc.2013-1279","volume":"98","author":"C Pihoker","year":"2013","unstructured":"Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab. 2013;98:4055\u201362. https:\/\/doi.org\/10.1210\/jc.2013-1279.","journal-title":"J Clin Endocrinol Metab"},{"key":"4272_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00125-016-4167-1","volume":"60","author":"BB Johansson","year":"2017","unstructured":"Johansson BB, Irgens HU, Molnes J, Sztromwasser P, Aukrust I, Juliusson PB, et al. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia. 2017;60:625\u201335. https:\/\/doi.org\/10.1007\/s00125-016-4167-1.","journal-title":"Diabetologia"},{"key":"4272_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12916-017-0977-3","volume":"15","author":"V Bansal","year":"2017","unstructured":"Bansal V, Gassenhuber J, Phillips T, Oliveira G, Harbaugh R, Villarasa N, et al. Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals. BMC Med. 2017;15:213. https:\/\/doi.org\/10.1186\/s12916-017-0977-3.","journal-title":"BMC Med"},{"key":"4272_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2337\/dc13-2248","volume":"37","author":"AJ Chakera","year":"2014","unstructured":"Chakera AJ, Spyer G, Vincent N, Ellard S, Hattersley AT, Dunne FP. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic diabetes in pregnancy cohort. Diabetes Care. 2014;37:1230\u201336. https:\/\/doi.org\/10.2337\/dc13-2248.","journal-title":"Diabetes Care"},{"key":"4272_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12916-019-1363-0","volume":"17","author":"X Donath","year":"2019","unstructured":"Donath X, Saint-Martin C, Dubois-Laforgue D, Rajasingham R, Mifsud F, Ciangura C, et al. Next-generation sequencing identifies monogenic diabetes in 16% of patients with late adolescence\/adult-onset diabetes selected on a clinical basis: a cross-sectional analysis. BMC Med. 2019;17:132. https:\/\/doi.org\/10.1186\/s12916-019-1363-0.","journal-title":"BMC Med"},{"key":"4272_CR12","doi-asserted-by":"publisher","unstructured":"Russ-Silsby J, Teles M, Hassan SS, Elbarbary NS, Ng\u1ecdc CTB, De Franco E. Global perspectives on monogenic forms of diabetes. Diabetologia. 2025. https:\/\/doi.org\/10.1007\/s00125-025-06495-3.","DOI":"10.1007\/s00125-025-06495-3"},{"key":"4272_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/pedi.13426","volume":"23","author":"SAW Greeley","year":"2022","unstructured":"Greeley SAW, Polak M, Nj\u00f8lstad PR, Barbetti F, Williams R, Castano L, et al. ISPAD clinical Practice consensus guidelines, 2022: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2022;23:1188\u2013211. https:\/\/doi.org\/10.1111\/pedi.13426.","journal-title":"Pediatr Diabetes"},{"key":"4272_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s11154-022-09749-2","volume":"23","author":"K Perge","year":"2022","unstructured":"Perge K, Nicolino M. Variable phenotypes of individual and family monogenic cases with hyperinsulinism and diabetes: a systematic review. Rev Endocr Metab Disord. 2022;23:1063\u201378. https:\/\/doi.org\/10.1007\/s11154-022-09749-2.","journal-title":"Rev Endocr Metab Disord"},{"key":"4272_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2337\/dc19-0747","volume":"43","author":"A Carlsson","year":"2020","unstructured":"Carlsson A, Shepherd M, Ellard S, Weedon M, Lernmark \u00c5, Forsander G, et al. Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish National cohort study. Diabetes Care. 2020;43:82\u201389. https:\/\/doi.org\/10.2337\/dc19-0747.","journal-title":"Diabetes Care"},{"key":"4272_CR16","doi-asserted-by":"publisher","first-page":"109908","DOI":"10.1016\/j.diabres.2022.109908","volume":"188","author":"F Mifsud","year":"2022","unstructured":"Mifsud F, Saint-Martin C, Dubois-Laforgue D, Bouvet D, Timsit J, Bellann\u00e9-Chantelot C, et al. Monogenic diabetes in adults: a multi-ancestry study reveals strong disparities in diagnosis rates and clinical presentation. Diabetes Res Clin Pract. 2022;188:109908. https:\/\/doi.org\/10.1016\/j.diabres.2022.109908.","journal-title":"Diabetes Res Clin Pract"},{"key":"4272_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.2337\/dc11-1243","volume":"35","author":"G Thanabalasingham","year":"2012","unstructured":"Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care. 2012;35:1206\u201312. https:\/\/doi.org\/10.2337\/dc11-1243.","journal-title":"Diabetes Care"},{"key":"4272_CR18","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2337\/diacare.28.7.1751","volume":"28","author":"A Stride","year":"2005","unstructured":"Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005;28:1751\u201356. https:\/\/doi.org\/10.2337\/diacare.28.7.1751.","journal-title":"Diabetes Care"},{"key":"4272_CR19","doi-asserted-by":"publisher","unstructured":"Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4:e118. https:\/\/doi.org\/10.1371\/journal.pmed.0040118.","DOI":"10.1371\/journal.pmed.0040118"},{"key":"4272_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1530\/EJE-09-0861","volume":"162","author":"SE Flanagan","year":"2010","unstructured":"Flanagan SE, Kapoor RR, Mali G, Cody D, Murphy N, Schwahn B, et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol. 2010;162:987\u201392. https:\/\/doi.org\/10.1530\/EJE-09-0861.","journal-title":"Eur J Endocrinol"},{"key":"4272_CR21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/dme.12487","volume":"31","author":"R Kawakita","year":"2014","unstructured":"Kawakita R, Hosokawa Y, Fujimaru R, Tamagawa N, Urakami T, Takasawa K, et al. Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients. Diabet Med J Br Diabet Assoc. 2014;31:1357\u201362. https:\/\/doi.org\/10.1111\/dme.12487.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"4272_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/dc09-0681","volume":"33","author":"AL Cuesta-Mu\u00f1oz","year":"2010","unstructured":"Cuesta-Mu\u00f1oz AL, Tuomi T, Cobo-Vuilleumier N, Koskela H, Odili S, Stride A, et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY). Diabetes Care. 2010;33:290\u201392. https:\/\/doi.org\/10.2337\/dc09-0681.","journal-title":"Diabetes Care"},{"key":"4272_CR23","doi-asserted-by":"publisher","unstructured":"Bellann\u00e9-Chantelot C, L\u00e9vy DJ, Carette C, Saint-Martin C, Riveline J-P, Larger E, et al. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J Clin Endocrinol Metab. 2011;96:E1346\u20131351. https:\/\/doi.org\/10.1210\/jc.2011-0268.","DOI":"10.1210\/jc.2011-0268"},{"key":"4272_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11892-018-1075-4","volume":"18","author":"HE Lebovitz","year":"2018","unstructured":"Lebovitz HE, Banerji MA. Ketosis-prone diabetes (flatbush diabetes): an emerging worldwide clinically important entity. Curr Diab Rep. 2018;18:120. https:\/\/doi.org\/10.1007\/s11892-018-1075-4.","journal-title":"Curr Diab Rep"},{"key":"4272_CR25","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.2337\/dc16-2462","volume":"40","author":"D Dubois-Laforgue","year":"2017","unstructured":"Dubois-Laforgue D, Cornu E, Saint-Martin C, Coste J, Bellann\u00e9-Chantelot C, Timsit J, et al. Diabetes, associated clinical Spectrum, long-term prognosis, and Genotype\/Phenotype correlations in 201 adult patients with hepatocyte nuclear factor 1B (HNF1B) molecular defects. Diabetes Care. 2017;40:1436\u201343. https:\/\/doi.org\/10.2337\/dc16-2462.","journal-title":"Diabetes Care"},{"key":"4272_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7326\/0003-4819-134-9_part_1-200105010-00008","volume":"134","author":"PJ Guillausseau","year":"2001","unstructured":"Guillausseau PJ, Massin P, Dubois-LaForgue D, Timsit J, Virally M, Gin H, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med. 2001;134:721\u201328. https:\/\/doi.org\/10.7326\/0003-4819-134-9_part_1-200105010-00008.","journal-title":"Ann Intern Med"},{"key":"4272_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1464-5491.2008.02359.x","volume":"25","author":"R Murphy","year":"2008","unstructured":"Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A & G mitochondrial point mutation. Diabet Med J Br Diabet Assoc. 2008;25:383\u201399. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02359.x.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"4272_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.2337\/db21-0520","volume":"71","author":"C Saint-Martin","year":"2022","unstructured":"Saint-Martin C, Bouvet D, Bastide M, Bellann\u00e9-Chantelot C. Gene Panel sequencing of patients with monogenic diabetes brings to light genes typically associated with syndromic presentations. Diabetes. 2022;71:578\u201384. https:\/\/doi.org\/10.2337\/db21-0520.","journal-title":"Diabetes"},{"key":"4272_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2337\/db21-0517","volume":"71","author":"K Colclough","year":"2022","unstructured":"Colclough K, Ellard S, Hattersley A, Patel K. Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of maturity-onset diabetes of the young. Diabetes. 2022;71:530\u201337. https:\/\/doi.org\/10.2337\/db21-0517.","journal-title":"Diabetes"},{"key":"4272_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11892-015-0702-6","volume":"16","author":"F Urano","year":"2016","unstructured":"Urano F. Wolfram syndrome: diagnosis, management, and treatment. Curr Diab Rep. 2016;16:6. https:\/\/doi.org\/10.1007\/s11892-015-0702-6.","journal-title":"Curr Diab Rep"},{"key":"4272_CR31","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: a multi-Society Practice guideline. J Clin Endocrinol Metab. 2016;101:4500\u201311. https:\/\/doi.org\/10.1210\/jc.2016-2466.","journal-title":"J Clin Endocrinol Metab"},{"key":"4272_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-022-02308-7","volume":"17","author":"H Mosbah","year":"2022","unstructured":"Mosbah H, Donadille B, Vatier C, Janmaat S, Atlan M, Badens C, et al. Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins). Orphanet J Rare Dis. 2022;17:170. https:\/\/doi.org\/10.1186\/s13023-022-02308-7.","journal-title":"Orphanet J Rare Dis"},{"key":"4272_CR33","doi-asserted-by":"publisher","first-page":"101730","DOI":"10.1016\/j.ando.2025.101730","volume":"86","author":"M-C Vantyghem","year":"2025","unstructured":"Vantyghem M-C, Nob\u00e9court E, Vatier C, Bismuth E, Deshuille C, Elarouci N, et al. Lipodystrophy and severe insulin resistance syndrome: epidemiological data from a French national rare diseases registry. Ann Endocrinol. 2025;86:101730. https:\/\/doi.org\/10.1016\/j.ando.2025.101730.","journal-title":"Ann Endocrinol"},{"key":"4272_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1172\/JCI37432","volume":"119","author":"RK Semple","year":"2009","unstructured":"Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119:315\u201322. https:\/\/doi.org\/10.1172\/JCI37432.","journal-title":"J. Clin. Invest"},{"key":"4272_CR35","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1074\/jbc.M115.685750","volume":"291","author":"BD Moore","year":"2016","unstructured":"Moore BD, Jin RU, Lo H, Jung M, Wang H, Battle MA, et al. Transcriptional regulation of X-Box-binding protein one (XBP1) by hepatocyte nuclear factor 4\u03b1 (HNF4\u0391) is vital to beta-cell function. J Biol Chem. 2016;291:6146\u201357. https:\/\/doi.org\/10.1074\/jbc.M115.685750.","journal-title":"J Biol Chem"},{"key":"4272_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical Genetics and Genomics and the Association for molecular pathology. Genet Med. 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"4272_CR37","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ajhg.2022.09.014","volume":"109","author":"UL Mirshahi","year":"2022","unstructured":"Mirshahi UL, Colclough K, Wright CF, Wood AR, Beaumont RN, Tyrrell J, et al. Reduced penetrance of MODY-associated HNF1A\/HNF4A variants but not GCK variants in clinically unselected cohorts. Am J Hum Genet. 2022;109:2018\u201328. https:\/\/doi.org\/10.1016\/j.ajhg.2022.09.014.","journal-title":"Am J Hum Genet"},{"key":"4272_CR38","doi-asserted-by":"publisher","unstructured":"Laver TW, Patel KA. Maturity onset diabetes of the young and beyond: the changing face of single-gene diabetes. Eur J Endocrinol. 2025;193:R25\u20139. https:\/\/doi.org\/10.1093\/ejendo\/lvaf172.","DOI":"10.1093\/ejendo\/lvaf172"},{"key":"4272_CR39","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/s42255-025-01372-0","volume":"7","author":"J Murray Leech","year":"2025","unstructured":"Murray Leech J, Beaumont RN, Arni AM, Chundru VK, Sharp LN, Colclough K, et al. Common genetic variants modify disease risk and clinical presentation in monogenic diabetes. Nat Metab. 2025;7:1819\u201329. https:\/\/doi.org\/10.1038\/s42255-025-01372-0.","journal-title":"Nat Metab"},{"key":"4272_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00125-001-0770-9","volume":"45","author":"A Stride","year":"2002","unstructured":"Stride A, Vaxillaire M, Tuomi T, Barbetti F, Nj\u00f8lstad PR, Hansen T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002;45:427\u201335. https:\/\/doi.org\/10.1007\/s00125-001-0770-9.","journal-title":"Diabetologia"},{"key":"4272_CR41","doi-asserted-by":"publisher","unstructured":"Colclough K, Saint-Martin C, Timsit J, Ellard S, Bellann\u00e9-Chantelot C. Clinical utility gene card for: maturity-onset diabetes of the young. Eur J Hum Genet EJHG. 2014;22. https:\/\/doi.org\/10.1038\/ejhg.2014.14.","DOI":"10.1038\/ejhg.2014.14"},{"key":"4272_CR42","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024;47:S179\u2013218. https:\/\/doi.org\/10.2337\/dc24-S010.","DOI":"10.2337\/dc24-S010"},{"key":"4272_CR43","doi-asserted-by":"publisher","unstructured":"Lanzinger S, Laubner K, Warncke K, Mader JK, Kummer S, Boettcher C, et al. Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: insights from the multicenter real-world DPV registry. J Diabetes. 2024;16:e70028. https:\/\/doi.org\/10.1111\/1753-0407.70028.","DOI":"10.1111\/1753-0407.70028"},{"key":"4272_CR44","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/0140-6736(92)91768-4","volume":"340","author":"G Velho","year":"1992","unstructured":"Velho G, Froguel P, Clement K, Pueyo ME, Rakotoambinina B, Zouali H, et al. Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet Lond Engl. 1992;340:444\u201348. https:\/\/doi.org\/10.1016\/0140-6736(92)91768-4.","journal-title":"Lancet Lond Engl"},{"key":"4272_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jama.2013.283980","volume":"311","author":"AM Steele","year":"2014","unstructured":"Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311:279\u201386. https:\/\/doi.org\/10.1001\/jama.2013.283980.","journal-title":"JAMA"},{"key":"4272_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molmet.2018.08.001","volume":"17","author":"AJ Chakera","year":"2018","unstructured":"Chakera AJ, Hurst PS, Spyer G, Ogunnowo-Bada EO, Marsh WJ, Riches CH, et al. Molecular reductions in glucokinase activity increase counter-regulatory responses to hypoglycemia in mice and humans with diabetes. Mol Metab. 2018;17:17\u201327. https:\/\/doi.org\/10.1016\/j.molmet.2018.08.001.","journal-title":"Mol Metab"},{"key":"4272_CR47","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00592-016-0859-8","volume":"53","author":"D Carmody","year":"2016","unstructured":"Carmody D, Naylor RN, Bell CD, Berry S, Montgomery JT, Tadie EC, et al. GCK-MODY in the US National monogenic diabetes registry: frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016;53:703\u201308. https:\/\/doi.org\/10.1007\/s00592-016-0859-8.","journal-title":"Acta Diabetol"},{"key":"4272_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00125-013-3075-x","volume":"57","author":"A Stride","year":"2014","unstructured":"Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2014;57:54\u201356. https:\/\/doi.org\/10.1007\/s00125-013-3075-x.","journal-title":"Diabetologia"},{"key":"4272_CR49","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/953","volume":"19","author":"AT Hattersley","year":"1998","unstructured":"Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet. 1998;19:268\u201370. https:\/\/doi.org\/10.1038\/953.","journal-title":"Nat Genet"},{"key":"4272_CR50","doi-asserted-by":"publisher","unstructured":"Ciangura C, Seco A, Saint-Martin C, Ancel P-Y, Bouvet D, Jacqueminet S, et al. Pregnancy and neonatal outcomes in women with GCK-MODY: an observational study based on standardised insulin modalities. Diabetologia. 2025. https:\/\/doi.org\/10.1007\/s00125-025-06363-0.","DOI":"10.1007\/s00125-025-06363-0"},{"key":"4272_CR51","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00125-020-05181-w","volume":"63","author":"WK Chung","year":"2020","unstructured":"Chung WK, Erion K, Florez JC, Hattersley AT, Hivert M-F, Lee CG, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD). Diabetologia. 2020;63:1671\u201393. https:\/\/doi.org\/10.1007\/s00125-020-05181-w.","journal-title":"Diabetologia"},{"key":"4272_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMcpc1913475","volume":"382","author":"MS Udler","year":"2020","unstructured":"Udler MS, Powe CE, Case A-TC. Case 6-2020.A 34-year-old woman with hyperglycemia. N Engl J Med. 2020;382:745\u201353. https:\/\/doi.org\/10.1056\/NEJMcpc1913475.","journal-title":"N Engl J Med"},{"key":"4272_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s001250050931","volume":"41","author":"B Isomaa","year":"1998","unstructured":"Isomaa B, Henricsson M, Lehto M, Forsblom C, Karanko S, Sarelin L, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia. 1998;41:467\u201373. https:\/\/doi.org\/10.1007\/s001250050931.","journal-title":"Diabetologia"},{"key":"4272_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1464-5491.2009.02913.x","volume":"27","author":"AM Steele","year":"2010","unstructured":"Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med J Br Diabet Assoc. 2010;27:157\u201361. https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02913.x.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"4272_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/1753-0407.12959","volume":"12","author":"A Haddouche","year":"2020","unstructured":"Haddouche A, Bellanne-Chantelot C, Rod A, Fournier L, Chiche L, Gautier J-F, et al. Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): clinical, radiological and pathological characteristics in a French series. J Diabetes. 2020;12:48\u201357. https:\/\/doi.org\/10.1111\/1753-0407.12959.","journal-title":"J Diabetes"},{"key":"4272_CR56","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","volume":"362","author":"ER Pearson","year":"2003","unstructured":"Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet Lond Engl. 2003;362:1275\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(03)14571-0.","journal-title":"Lancet Lond Engl"},{"key":"4272_CR57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1464-5491.2009.02690.x","volume":"26","author":"M Shepherd","year":"2009","unstructured":"Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med J Br Diabet Assoc. 2009;26:437\u201341. https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02690.x.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"4272_CR58","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2337\/diacare.29.02.06.dc05-1314","volume":"29","author":"T Tuomi","year":"2006","unstructured":"Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care. 2006;29:189\u201394. https:\/\/doi.org\/10.2337\/diacare.29.02.06.dc05-1314.","journal-title":"Diabetes Care"},{"issue":"27","key":"4272_CR59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/pedi.12772","volume":"19","author":"AT Hattersley","year":"2018","unstructured":"Hattersley AT, Greeley SAW, Polak M, Rubio-Cabezas O, Nj\u00f8lstad PR, Mlynarski W, et al. ISPAD clinical Practice consensus guidelines, 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2018;19(27):47\u201363. https:\/\/doi.org\/10.1111\/pedi.12772.","journal-title":"Pediatr Diabetes"},{"key":"4272_CR60","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2337\/dc13-3007","volume":"37","author":"SH \u00d8stoft","year":"2014","unstructured":"\u00d8stoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014;37:1797\u2013805. https:\/\/doi.org\/10.2337\/dc13-3007.","journal-title":"Diabetes Care"},{"key":"4272_CR61","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.2337\/db20-0074","volume":"69","author":"AS Christensen","year":"2020","unstructured":"Christensen AS, H\u00e6dersdal S, Storgaard H, Rose K, Hansen NL, Holst JJ, et al. GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1\u03b1 mutation carriers. Diabetes. 2020;69:1989\u20132002. https:\/\/doi.org\/10.2337\/db20-0074.","journal-title":"Diabetes"},{"key":"4272_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s43856-024-00556-1","volume":"4","author":"RN Naylor","year":"2024","unstructured":"Naylor RN, Patel KA, Kettunen JLT, M\u00e4nnist\u00f6 JME, St\u00f8y J, Beltrand J, et al. Precision treatment of beta-cell monogenic diabetes: a systematic review. Commun Med. 2024;4:145. https:\/\/doi.org\/10.1038\/s43856-024-00556-1.","journal-title":"Commun Med"},{"key":"4272_CR63","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s12020-017-1341-2","volume":"57","author":"J Hohendorff","year":"2017","unstructured":"Hohendorff J, Szopa M, Skupien J, Kapusta M, Zapala B, Platek T, et al. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. Endocrine. 2017;57:272\u201379. https:\/\/doi.org\/10.1007\/s12020-017-1341-2.","journal-title":"Endocrine"},{"key":"4272_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/embo-reports\/kvd071","volume":"1","author":"M Pontoglio","year":"2000","unstructured":"Pontoglio M, Pri\u00e9 D, Cheret C, Doyen A, Leroy C, Froguel P, et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1:359\u201365. https:\/\/doi.org\/10.1093\/embo-reports\/kvd071.","journal-title":"EMBO Rep"},{"key":"4272_CR65","doi-asserted-by":"publisher","unstructured":"Rudland VL, Price SAL, Hughes R, Barrett HL, Lagstrom J, Porter C, et al. ADIPS, 2020 guideline for pre-existing diabetes and pregnancy. Aust N Z J Obstet Gynaecol. 2020;60:E18\u201352. https:\/\/doi.org\/10.1111\/ajo.13265.","DOI":"10.1111\/ajo.13265"},{"key":"4272_CR66","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00125-005-1738-y","volume":"48","author":"ER Pearson","year":"2005","unstructured":"Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden H J, Lumb PJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia. 2005;48:878\u201385. https:\/\/doi.org\/10.1007\/s00125-005-1738-y.","journal-title":"Diabetologia"},{"key":"4272_CR67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/jmedgenet-2013-102066","volume":"51","author":"AJ Hamilton","year":"2014","unstructured":"Hamilton AJ, Bingham C, McDonald TJ, Cook PR, Caswell RC, Weedon MN, et al. The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a \u03b2 cell phenotype. J Med Genet. 2014;51:165\u201369. https:\/\/doi.org\/10.1136\/jmedgenet-2013-102066.","journal-title":"J Med Genet"},{"key":"4272_CR68","doi-asserted-by":"publisher","unstructured":"Broome DT, Tekin Z, Pantalone KM, Mehta AE. Novel use of GLP-1 receptor agonist therapy in HNF4A-MODY. Diabetes Care. 2020;43:e65. https:\/\/doi.org\/10.2337\/dc20-0012.","DOI":"10.2337\/dc20-0012"},{"key":"4272_CR69","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00125-021-05581-6","volume":"65","author":"JM Locke","year":"2022","unstructured":"Locke JM, Dusatkova P, Colclough K, Hughes AE, Dennis JM, Shields B, et al. Association of birthweight and penetrance of diabetes in individuals with HNF4A-MODY: a cohort study. Diabetologia. 2022;65:246\u201349. https:\/\/doi.org\/10.1007\/s00125-021-05581-6.","journal-title":"Diabetologia"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04272-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04272-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04272-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:14:33Z","timestamp":1781644473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04272-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":69,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["4272"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04272-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The National Diagnostic and Care Protocol (PNDS) for MODY was developed by accredited reference and competence PRISIS centers, with methodological support from the French National Health Authority (HAS), in application of the provisions of the National Rare Diseases Plan 2005\u20132023. This new version is placed under the sole editorial responsibility of the PRISIS network.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Group statement"}},{"value":"The authors declare that they have no competing interests related to the content of the present manuscript. BD reports past consulting fees\/meeting fees from Sanofi and speaking fees from Novartis, Lilly, Sanofi. CVa reports consulting fees\/meeting fees from Chiesi, Lilly, MSD, Menarini, NovoNordisk, Sanofi, Aegerion, AstraZeneca, Abbott, Advanz pharma, Amryt, Rhythm, and research funding from Sanofi. CVi reports lecture fees from Amryt Pharmaceuticals (now Chiesi Farmaceutici), Sanofi and Gilead. EB reports consulting fees\/meeting fees from Medtronic, Abbot, Lilly, Insulet, speaking fees from NovoNordisk, Lilly, Orkyn, Abbot, DinnoSant\u00e9 and research funding from Lilly. IT reports consulting fees\/meeting fees from MSD, Pfizer SAS, Pharma Dom, Novartis, Astra Zeneca, Sanofi, Recordati Rare Disease. JCN reveiced research grants from Bayer and Ipsen. MCV served as investigator in the APL-22 clinical study sponsored by Chiesi Farmaceutici. PB reports consulting fees\/meeting fees from Abbott, Lilly, NovoNordisk, Dexcom, Sanofi. PG reports consulting fees\/meeting fees from Abbott, Abbvie, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, and Sanofi.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}